Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Theriva Biologics ( (TOVX) ) has issued an update.
Theriva Biologics has announced that the European Commission granted orphan medicinal product designation to its leading candidate VCN-01 for treating retinoblastoma, highlighting the urgent need for new therapies. This designation, following similar recognition by the FDA, underscores VCN-01’s potential to transform treatment options, offering significant benefits to patients by enhancing chemotherapy effectiveness and improving immune response against tumors.
For a thorough assessment of TOVX stock, go to TipRanks’ Stock Analysis page.